https://www.selleckchem.com/pr....oducts/act001-dmamcl
Results Patients with recovery of menstruation after chemotherapy less frequently had lymph node involvement at diagnosis (45% vs 66%, p = 0.001). After a median follow-up of 6.7 years, the adjusted hazard ratios were 1.45 (95% CI 0.83-2.54) for DFS and 1.19 (95% CI 0.71-1.98) for OS. Conclusion No significantly increased recurrence risk was found for hormone receptor-negative BC patients with recovery of menstruation after chemotherapy. However, the outcome of the multivariable model is not reassuring and a potentially increased
Like
Comment
Share
